



Sleep-Aids Derived from Natural Products

Zhenzhen Hu¹, Seikwan Oh², Tae-Woo Ha³, Jin-Tae Hong³ and Ki-Wan Oh^{3,*}

¹Department of Pathophysiology, College of Basic Medicine, Nanchang University, Nanchang, Jiangxi 33006, China

²Department of Molecular Medicine and TIDRC, School of Medicine, Ewha Womans University, Seoul 07985,

³Department of Pharmacy, College of Pharmacy, Chungbuk National University, Osong 28160, Republic of Korea

Abstract

Although drugs such as barbiturates and benzodiazepines are often used for the treatment of insomnia, they are associated with various side effects such as habituations, tolerance and addiction. Alternatively, natural products with minimal unwanted effects have been preferred for the treatment of acute and/or mild insomnia, with additional benefits of overall health-promotion. Basic and clinical researches on the mechanisms of action of natural products have been carried out so far in insomnia treatments. Recent studies have been focusing on diverse chemical components available in natural products, with an interest of developing drugs that can improve sleep duration and quality. In the last 15 years, our co-workers have been actively looking for candidate substances from natural products that can relieve insomnia. This review is, therefore, intended to bring pharmacological data regarding to the effects of natural products on sleep duration and quality, mainly through the activation of GABA_A receptors. It is imperative that phytochemicals will provide useful information during electroencephalography (EEG) analysis and serve as an alternative medications for insomnia patients who are reluctant to use conventional drugs.

Key Words: Insomnia, Sleep, Natural products, Pharmacological mechanisms, Electroencephalography (EEG)

AN OVERVIEW OF INSOMNIA

Most people often or chronically experience insomnia characterized by difficulty in falling asleep, overnight loss of sleep, trouble to resume sleep, waking up too early, unable to re-freshed after sleep and loss of working time due to tiredness and faintness (National Sleep Foundation, USA). Sleep is vital to maintain mood, memory, cognitive function by restoring the majority of human body systems through endocrine and immune functions. Therefore, sleep is one of the most instinctive and essential physiological demand for normal life such as maintaining health and mental stability. Meanwhile, humans may suffer from various sleep disorders, including insomnia, hypersomnia, narcolepsy, and sleep apnea (Jacobson *et al.*, 2017).

On the other hand, insomnia has been associated with psychiatric conditions, unhealthy sleep habits, specific excitatory substances, and/or certain biological factors. Moreover, medical conditions with comorbidities may aggravate these insomnia related abnormalities (Starks *et al.*, 2018).

So far, studies have been focusing on various molecules leading into insomnia. Many of these molecules involved in sleep-wake regulation are produced by specific brain regions with widespread projections. Research findings have been largely interpreted within the context of hyperarousal hypothesis. For instance, insomnia patients with GABA in the occipital cortex has been reported to be consistent with the hyperarousal model of insomnia. In addition, emotional and cognitive systems lead to suppression of sleep-promoting regions such as the ventrolateral preoptic area (VLPO) (Wang and Liu, 2016; Bourcier *et al.*, 2018). In addition, orexin/hypocretin neurons of the lateral hypothalamus project to all of the sleep/insomnia arousal-promoting centers in the brainstem and hypothalamus thereby reinforcing their activity to play on important roles in sleep. The pathophysiological understanding of insomnia may provide important information regarding how, and under what conditions, the disorder develops and is maintained as well as potential targets for prevention and treatment (Jacobson *et al.*, 2017).

Open Access <https://doi.org/10.4062/biomolther.2018.099>

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (<http://creativecommons.org/licenses/by-nc/4.0/>) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Received May 30, 2018 Revised Jun 7, 2018 Accepted Jun 7, 2018

Published Online Jun 22, 2018

***Corresponding Author**

E-mail: kiwan@chungbuk.ac.kr

Tel: +82-43-261-2827, Fax: +82-43-261-2827

ANIMAL SURGERY & EEG RECORDING

Rats were anesthetized with pentobarbital (50 mg/kg, i.p.) and the transmitter was implanted for recording EEG via telemetry as described earlier (Sanford *et al.*, 2006). Briefly, the body of the transmitter was subcutaneously implanted just posterior to the scapula with three sutures for stabilization. The transmitters led subcutaneously to the skull, and the bare ends were placed in contact with the dura through holes in the skull. The electrodes were anchored to the skull with screws and dental cement. All of the surgical procedures were performed stereotaxically under aseptic conditions (Yang *et al.*, 2011b; Perentos *et al.*, 2017).

For telemetric recording of signals from cortical EEG, the gain of transmitters was set at $-0.5/+0.5$ volts per units $\times 2$ with raw signals ranging from 0.5 to 0.0 Hz and these signals were processed by Data Sciences analog converter and routed to an analog-to-digital (AD) converter (Eagle PC30, Data Sciences International). The AD converter digitized the EEG and activity signals; subsequently data were transferred to a computer and graphically displayed. An on-line fast Fourier transformation (FFT) analyzed EEG data and generated power density values from 0.0 to 20.0 Hz at a resolution of 0.5 Hz. The FFT data were further averaged between 0 to 20 Hz at 10-s intervals. The sleep data and FFT results were saved to the hard disk every 10 s for additional off-line analysis. Movements of the animal in relation to the telemetry receiver generated transistor-transistor logic pulses that were collected and counted as a measure of activity. The signal of EEG was measured for 6 hours between 11:00 am and 5:00 pm. Each group has 5-6 rats (Hu *et al.*, 2013).

Time elapsed in wakefulness, NREM sleep or REM sleep was determined from digitized data within 10 s using the animal sleep analysis software Sleep-Sign 2.1 (Kissei Comtec, Matsumoto, Japan). Briefly, the software identifies wakefulness as a high-frequency with low-amplitude of EEG whereas in NREM sleep, it showed spindles interspersed with slow waves compared with REM sleep characterized by δ -waves (0.75 to 4.0 Hz) and θ -wave activity (5.0 to 9.0 Hz) with peak value at 7.5 Hz.

MOLECULAR TARGETS FOR INSOMNIA THERAPY

Several efficacious pharmacological treatments for insomnia target to various aspects of identified pathophysiological processes. For instance, GABA is released from the terminal of specific inhibitory neurons and then it binds to its receptors, thereby enhancing chloride influx and facilitates GABA_A-ergic transmission (Olsen, 1981; Ticku and Maksay, 1983). This effect is supported by benzodiazepines and barbiturates by their agonistic effects on the GABA_A receptors. Thus, their binding to the allosteric site of the receptors enhances the affinity of the GABA-binding site. However, four different types of GABA_A receptor subunits have been described, each of which encloses different membranes. Likewise, the critical step in GABA biosynthesis is the decarboxylation of glutamate by glutamic acid decarboxylase (GAD), which exists in two different isoforms, GAD₆₅ and GAD₆₇. The level of GAD₆₅ and GAD₆₇ is reported to be up-regulated in the GABA_A-ergic interneurons. With this intricate nature, GABA_A receptors have been known to play an important role in the modulation of barbiturate-in-

duced sleeping through interaction with GABA_A-ergic systems (Doghramji, 2006). GABA-benzodiazepine receptor agonists which are generally effective in the treatment of insomnia can promote sleep by enhancing the widespread function of GABA. This suggests that new compounds can be developed for specific molecular targets with known sleep-related actions. Apart from this, non-GABA_A-chloride channel receptor complex agonist such as melatonin (MT) receptor agonist, 5-HT_{1A} receptor agonist, orexin receptor agonist, adenosine receptor agonist and histamine receptor antagonist have been suggested for the treatment of insomnia (Dujardin *et al.*, 2018). Benzodiazepines are currently the most well-known and most frequently prescribed hypnotic medications, although their use in recent years is being replaced by newer non-benzodiazepine hypnotic drugs, so-called "z-drugs" such as eszopiclone, zolpidem and zaleplon. As these non-benzodiazepine medications are generally believed to be better and safer than earlier generations of sedatives, they have still generated some controversy and discussion regarding side-effects (Schwartz *et al.*, 2017).

The possible role of serotonin (5-HT) in human sleep disorders has been considered. Ursin provides an excellent overview of the evolving concept of the role of serotonin (5-HT) in sleep, supporting the sleep-promoting effects (Ursin, 2002). The role of specific receptor subtypes in sleep-wake regulation has been focused. Gronli reported the effect of certain drugs affecting 5-HT_{1A} and 5-HT_{1B} receptors, which have affinity at the pre- and post-synaptic receptors, later including inhibitory auto-receptors on serotonin neurons, themselves (Gronli *et al.*, 2007). In particular, 5-HT_{1A/1B}, plays a crucial role in regulating serotonin transmission in the brain. Recent studies have also suggested a role for the 5-HT_{1B} receptor in depression, anxiety and sleep. 5-HT_{1B} antagonists reduce the latency to onset of anxiolytic behavior and play a role in stress regulation with activity comparable to diazepam (Tatarczynska *et al.*, 2004). However, some antagonists of serotonin may increase non-rapid eye movement (NREM) sleep. The findings are complex, but support the role of 5-HT_{1A}, 5-HT_{1B} and 5-HT₇ receptors in REM control (Leiser *et al.*, 2015).

Non-benzodiazepine hypnotics such as diphenhydramine and doxylamine have been used for the treatment of insomnia. The sedative effect of antihistamines is mainly achieved by targeting the histamine receptors in arousal systems. More recently, there has been progress in the development of orexin receptor antagonists for the treatment of insomnia. Orexin systems target on the promotion of arousal of brainstem/hypothalamic arousal centers (Mieda, 2017). In addition to this, other molecular targets such as melatonin and adenosine have been suggested for the treatment of insomnia (Di Bella *et al.*, 2017).

Various compounds, with novel approaches are being evaluated currently as possible insomnia treatments. Currently, Korea FDA is reviewing new applications for innovative sleep-promoting herbs. Clinical indications have been developed for insomnia associated with problem of sleep onset, sleep maintenance, and middle-of-the-night awakenings. Alternative approaches to treating insomnia have included an off-label basis for insomnia, over-the-counter sleep aids, and assorted unregulated substances marketed to enhance sleep. Substances regarded as appropriate hypnotics are those which prevent continuous awakenings, shorten the period of latency for sleep initiation and increase sleep duration, besides displaying low toxicity.



Fig. 1. EEG measurement experiment in the rats. 1. To measure EEG changes, the rats were sutured after implantation of the transmitter body on the back of male rats. 2. The electrode is inserted and fixed with dental cement after puncturing the skull. 3. After one week of recovery from surgery, EEG is recorded. 4. The sleep architecture is analyzed based on the EEG record, which is received on the computer.

Key physiological measurements indicators of sleep include electroencephalography (EEG) of brain waves, electrooculography (EOG) of eye movements, electromyography (EMG) of skeletal muscle activity. Simultaneous collection of these measurements is called polysomnography, and can be performed in a specialized sleep laboratory (Rundell and Jones, 1990). Sleep researchers also use simplified electrocardiography (ECG) for cardiac activity and actigraphy for motor movements (Jafari and Mohsenin, 2010). This has promoted the search for alternative approaches such as the employment of phytotherapeutic agents. Animal behavioral experiments were done after surgery and agent treatment (Fig. 1).

NATURAL PRODUCTS WHICH HAVE PROVEN TO BE EFFECTIVE FOR SLEEPING FROM OUR LABORATORY

A number of medicinal plants are traditionally endowed with anxiolytic or sedative properties. This has motivated the searching of phytotherapeutic agents, which has been used in animal behavioral experiments performed by surgery (Fig. 1). In this context, there is a lot of information in medicinal plants possessing sedative and hypnotic properties. Here, we describe some natural products studied in our laboratory. These are magnolia (*Magnolia officinalis*, Magnoliaceae), Semen zizyphi spinosae (*Zizyphus jujube* Mill. var. *spinosa* Rhamnaceae), sinomenine (*Sinomenium acutum* Menispermaceae), decursinol (*Angelica gigas*, Umbelliferae), rosemary (*Perilla frutescens*, Lamiaceae), *Euphoria longan* (Spindaceae), Ginseng (*Panax ginseng*, Araliaceae), EGCG (Epigallocatechin-3-O-gallate, *Camellia sinensis*), *Chrysanthemum morifolium* (Asteraceae), Apigenin (*Circium japonicum*, Asteraceae) and some others that possess sedative effects (Fig. 2).

Magnolia (*M. obovate*, *M. officinalis*, Magnoliaceae) has been traditionally used for the treatment of thrombotic stroke, depression, anxiety, and inflammatory and neuronal diseases in oriental countries for a long time (Watanabe *et al.*, 1983; Hirano, 1991; Lo *et al.*, 1994). Biophenolic compounds such as magnolol, honokiol, and obovatol isolated from *M. obovate*/ and *M. officinalis* have been found to be anxiolytic and mus-

cle relaxant (Maruyama *et al.*, 1998; Seo *et al.*, 2007; Han *et al.*, 2010). From a previous experiment, it was reported that obovatol has anxiolytic-like effects in animal models, and enhanced pentobarbital-induced sleep suggesting that these effects are involved in GABA/benzodiazepine receptor complex (Seo *et al.*, 2007; Ma *et al.*, 2009b). In addition, research has shown that magnolol and honokiol are the primary active components of *M. officinalis* and they are positive allosteric modulators of GABA_A receptors. In addition, they have shown to increase the density of GABA_A receptors that possess alpha subunits and this has been a mechanism followed by diazepam, a benzodiazepine sometimes used to treat insomnia, (Ma *et al.*, 2008, 2009b; Lee *et al.*, 2010). All together, these effects increase GABA activity, which promotes relaxation and reduces anxiety. Magnolol increased the amount of REM and NREM sleep via the GABA_A receptors (Chen *et al.*, 2012). Particularly, magnolia bark has been used for human treatment as an anxiolytic, helping to lower anxiety, depression, reduce stress, and facilitating sleep. These effects could be indicators of its positive potential as a natural sleep aiding agent.

Semen zizyphi spinosae (Rhamnaceae, the dried seed of *Zizyphus jujube* Mill var. *spinosa*) has been used as a tranquilizer, an anxiolytic and anticonvulsant in oriental countries, and also has been prescribed for the treatment of insomnia and anxiety (Park *et al.*, 2004). It was reported that sanjoinine, which is a major alkaloid compound, and cyclopeptides from Semen zizyphi spinosae have shown anxiolytic-like effects in the elevated plus-maze, hole-board test and open field test, and these effects may be mediated by GABA_A-ergic transmission (Han *et al.*, 2008). Sanjoinine A and cyclopeptide fraction from Semen zizyphi spinosae exert hypnotic effect and/or enhances pentobarbital-induced sleeping behaviors (Ma *et al.*, 2008; Han *et al.*, 2009). Sanjoinine A in combination with muscimol showed synergistic effects on pentobarbital-induced sleeping and increased Cl⁻ influx in a similar way as pentobarbital. Sanjoinine A also showed similar effects with muscimol potentiating Cl⁻ influx inducing the effects of low dose pentobarbital. This indicated that sanjoinine A might act on GABA_A receptor to induce Cl⁻ channel opening, and modulate pentobarbital-induced pharmacological properties like a GABA_A receptor agonist (Ma *et al.*, 2007). Moreover, cyclo-




Fig. 2. Chemical structures originated from natural products which have been to be effective for sleep from our laboratory.

peptide alkaloid fraction of semen *zizyphi spinosae* increased pentobarbital-induced sleeping behaviors, through activation of GABA receptor Cl^- channels (Ma *et al.*, 2008). However, it has been suggested for high affinity for 5-HT_{1a} and 5-HT₂ receptors in *in vivo* analysis (Yi *et al.*, 2007).

Sinomenine, an alkaloid derived from *Sinomenium acutum*, is a chief ingredient that has been reported to have a variety of pharmacological properties including anxiolytic effects (Rao *et al.*, 2017). From a recent experiment, sinomenine enhanced pentobarbital-induced sleeping behaviors, and modulate sleep architecture via GABA_A-ergic systems in rodents, ultimately increasing NREM sleep.

The most abundant GABA_A receptor subunit compositions, $\alpha 1$, $\beta 2$ and $\gamma 2$, are related to the hypnotic/sedative effect of GABA_A receptors (Rudolph and Möhler, 2006). Previous studies have shown that $\alpha 1$ subunit was associated with sedation (Rudolph and Feiger, 1999; McKernan *et al.*, 2000). Whereas $\alpha 2/3$ subunits were associated with anxiety (Löw *et al.*, 2000; Crestani *et al.*, 2001), $\alpha 5$ subunit was associated with temporal and spatial memory (Collinson *et al.*, 2002; Crestani *et al.*, 2002). Sinomenine non-selectively activated these subunits of GABA_A receptors. During our experiment, major subunits of GABA_A receptor were over-expressed by sinomenine except for $\alpha 3$ and $\alpha 5$ subunits.

Decursinol is one of the major components of *Angelica gigas* (Umbelliferae) which has been used for a long time as a traditional folk medicine in oriental countries. This herb has been used traditionally for the treatment of psychosomatic dis-

ease such as excess stress, anxiety, depression and insomnia. It has been reported that the essential oil components of *Angelica gigas* exhibited anxiolytic-like effects in rodent tests (Chen *et al.*, 2004). Similarly, Japanese Angelica root extract reversed stress-induced loss of sleep in pentobarbital-induced sleeping in mice through the inhibition of the central noradrenergic or the activation of GABA_A receptors (Matsumoto *et al.*, 1998). Decursinol increased the number of sleeping animals in the sub-hypnotic dosage and modulated sleep architectures, most likely by increasing the protein expression of glutamic acid decarboxylase (GAD_{65/67}) and GABA_A receptors subtypes. On the other hand, decursinol potentiates pentobarbital-induced sleeping behaviors through the activation of GABA_A-ergic systems. Altogether suggest that decursinol, can be useful agent for the treatment of insomnia (Woo *et al.*, 2017).

Rosemary (from *Perilla frutescens*, Lamiaceae) has been used as a folk remedy for sedation in oriental countries. So far, several studies have shown that *Perilla frutescens* has sedative effect (Takeda *et al.*, 2002; Johnston *et al.*, 2006). Rosemary contains a number of phytochemicals, including rosmarinic acid, camphor, caffeic acid, ursolic acid, betulinic acid, carnosic acid and carnosol (Vallverdú-Queralt *et al.*, 2014). Rosmarinic acid belonging to the phenolic compounds is a constituent of *Perilla frutescens* (Igarashi and Miyazaki, 2013; Rašković *et al.*, 2014). Many of the phenolic compounds originating from plants have been known to affect the GABA-ergic systems (Johnston *et al.*, 2006). In addition, rosmarinic acid inhibited GABA transaminase (GABA-T) *in vitro* (Awad *et al.*, 2009), and increased the protein expression of GAD_{65/67} and GABA_A receptors subunits except $\beta 1$ subunit. Rosmarinic acid augmented pentobarbital-induced sleeping behaviors through GABA_A-ergic transmission. It is suggested that rosmarinic acid may be useful agent for the treatment of insomnia (Kwon *et al.*, 2017).

Euphoria longan (or *Dimocarpus longan*, Spindaceae) is commonly consumed as the dried fruit of *Euphoria longana*. Phytochemicals such as gallic acid, ellagic acid and corilagin (ellagitannin) were identified from the peel, seed and pulp of its fruit (Rang-Kadilok). The pulp of the dried fruit and fresh *Longanae* Arillus, has been used for the treatment of anxiety and insomnia in Asian countries. The extract of *Longanae* Arillus was proven to have anxiolytic activity (Okuyama *et al.*, 1999). From our experiment, methanol extract of *Longanae* Arillus was proven to prolong sleeping time and reduced pentobarbital-induced sleep onset in rodents through GABA_A-ergic systems (Ma *et al.*, 2009b). Methanol extract of *Longanae* Arillus regulated sleep architectures and EEG power spectra in restraint-stressed rats (Ma *et al.*, 2009b).

Ginseng (*Panax ginseng*, Araliaceae) may be in part related to maintaining sleep and wakefulness, and alter EEG spectra of sleep-wake stage in mice (Ma *et al.*, 2008, 2009a, 2009b; Yang *et al.*, 2011b). *Panax quinquefolium* (American ginseng) were reported to have sleeping-modulating effects. Saponin fraction of *Panax ginseng* extract prolonged the duration of hexobarbital-induced sleep in mice (Takagi *et al.*, 1972). In addition, red ginseng extract increased total sleep time and NREM sleep (Ma *et al.*, 2008; Yang *et al.*, 2011a). Majonosides R2, a major saponin of *Panax vietnamensis* restored the hypnotic activity of pentobarbital, which was decreased by psychological stresses (Nguyen *et al.*, 1993). Ginsenoside Rg3-standarized ginseng extract showed anti-stress effects and enhanced sleeping in restraint stressed animals (Kim *et*

al., 2010). There are evidences to suggest that the regulation of GABA_A-ergic transmission is one of target for the sedative actions of ginseng (Kimura *et al.*, 1994; Cha *et al.*, 2005; Park *et al.*, 2005). In human study, it has been confirmed that ginseng could improve the quality of sleep (Han *et al.*, 2013). Korea red ginseng increased NREM sleep via GABA_A-ergic systems (Lee *et al.*, 2012).

EGCG (Epigallocatechin-3-O-gallate) is a major component of green tea (*Camellia sinensis*) which is a popular beverage worldwide. However, green tea contains caffeine and EGCG. One is stimulant caffeine, and the other is EGCG which may be sedative. From our experiment, it was interesting that only EGCG from green tea augmented pentobarbital-induced sleeping time through Cl⁻ channel activation (Park *et al.*, 2011). This may suggest that EGCG counteracts caffeine-induced stimulant effects such as hyperactivity, arousal and anxiogenic effects (Park *et al.*, 2010). Anxiolytic effects and enhancement of sleep by EGCG also could be mediated by GABA_A-ergic systems (Bae *et al.*, 2002; Campbell *et al.*, 2004; Vignes *et al.*, 2006; Haque *et al.*, 2008; Park *et al.*, 2011).

Chrysanthemum morifolium (Asteraceae). The flower *Chrysanthemum morifolium* is a medicinal herb that has been used for tea preparation in oriental countries. *Chrysanthemum* sp contains flavonoids, phenols, cinnamic acids and on. The dry flower of *Chrysanthemum morifolium* in tea and pillow has been traditionally used for the treatment of insomnia in Korea. Ethanol extract of *Chrysanthemum morifolium* augments pentobarbital-induced sleeping behaviors through activation of Cl⁻ channels (Kim *et al.*, 2011).

Apigenin (from *Cirium japonicum*, Asteraceae) found in many plants, is a natural product belonging to flavonoids that are the aglycone of several naturally occurring glycosides. Apigenin is a weak ligand for central benzodiazepine receptors *in vitro* and exerts anxiolytic and slight sedative effects in an animal model (Viola *et al.*, 1995). Apigenin shows second-order positive modulatory activity at GABA_A receptors (Campbell *et al.*, 2004; Rosi *et al.*, 2004). It was reported that enhancement of pentobarbital-induced sleep by apigenin is mediated by GABA_A receptors through Cl⁻ channel complex activation (Kim *et al.*, 2012).

Others. Some natural products such as Polygalae Radix (3,4,5-trimethoxycinnamic acid), Gastrodiae Rhizoma (4-hydroxybenzaldehyde), *Poria cocos* (pachymic acid), Rhycho-philline (*Uncariae Ramulus et Uncus*) and Perilla Herba, were studied whether they enhance sleep or not (Lee *et al.*, 2013; Choi *et al.*, 2014; Shah *et al.*, 2014; Choi *et al.*, 2015; Shah *et al.*, 2015; Kwon *et al.*, 2017). From the behavioral and molecular data, those natural products augmented pentobarbital-induced sleep, and modulated sleep architectures of EEG spectra in rodents. The increase of sleep seems to be mediated through GABA_A-benzodiazepine receptors Cl⁻ channel complex.

However, cordycepin (*Cordyceps militaris/sinensis*) increased theta waves power density during NREM sleep. Adenosine receptors (AR) subtypes (A1, A2A and A2B) were over-expressed by cordycepin, and they are showing non-specific AR activation (Hu *et al.*, 2013).

CONCLUSION

Up to date, over the counter sleep aiding agents have been

introduced. St. John's wort (*Pipericum perforatum*), Kava kava (*Piper methysticum*), Valerian (*Valeriana officinalis*) and Passion flower (*Passiflora incarnata*) and other herbs, which have been used for the treatment of insomnia become popular as an alternative medicine. Natural products which have been proven to be effective for sleeping from our laboratory are reviewed. However, preclinical and clinical studies are needed to evaluate the precise effects of natural products for the treatment of insomnia.

CONFLICT OF INTEREST

All authors declare no conflict of interest.

ACKNOWLEDGMENTS

This research was supported by the National Research Foundation (NRF) grant funded by the Korea government, Ministry of Science, ICT & Future Planning (MRC 2010-0029355).

REFERENCES

- Awad, R., Muhammad, A., Durst, T., Trudeau, V. L. and Arnason, J. T. (2009) Bioassay-guided fractionation of lemon balm (*Melissa officinalis* L.) using an *in vitro* measure of GABA transaminase activity. *Phytother. Res.* **23**, 1075-1081.
- Bae, Y. C., Choi, B. J., Lee, M. G., Lee, H. J., Park, K. P., Zhang, L. F., Honma, S., Fukami, H., Yoshida, A. and Ottersen, O. P. (2002) Quantitative ultrastructural analysis of glycine- and γ -aminobutyric acid-immunoreactive terminals on trigeminal α - and γ -motoneuron somata in the rat. *J. Comp. Neurol.* **442**, 308-319.
- Bourcier, E., Korb-Savoldelli, V., Hejblum, G., Fernandez, C. and Hindle, P. (2018) A systematic review of regulatory and educational interventions to reduce the burden associated with the prescriptions of sedative-hypnotics in adults treated for sleep disorders. *PLoS ONE* **13**, e0191211.
- Campbell, E. L., Chebib, M. and Johnston, G. A. (2004) The dietary flavonoids apigenin and (-)-epigallocatechin gallate enhance the positive modulation by diazepam of the activation by GABA of recombinant GABA_A receptors. *Biochem. Pharmacol.* **68**, 1631-1638.
- Cha, H.-Y., Park, J.-H., Hong, J.-T., Yoo, H.-S., Song, S., Hwang, B.-Y., Eun, J.-S. and Oh, K.-W. (2005) Anxiolytic-like effects of ginsenosides on the elevated plus-maze model in mice. *Biol. Pharm. Bull.* **28**, 1621-1625.
- Chen, C.-R., Zhou, X.-Z., Luo, Y.-J., Huang, Z.-L., Urade, Y. and Qu, W.-M. (2012) Magnolol, a major bioactive constituent of the bark of *Magnolia officinalis*, induces sleep via the benzodiazepine site of GABA_A receptor in mice. *Neuropharmacology* **63**, 1191-1199.
- Chen, C. D., Welsbie, D. S., Tran, C., Baek, S. H., Chen, R., Vessella, R., Rosenfeld, M. G. and Sawyers, C. L. (2004) Molecular determinants of resistance to antiandrogen therapy. *Nat. Med.* **10**, 33.
- Choi, J. J., Kim, Y. S., Kwon, Y. O., Yoo, J. H., Chong, M. S., Lee, M. K., Hong, J. T. and Oh, K. W. (2015) 4-hydroxybenzaldehyde, one of constituents from *Gastrodiae rhizoma* augments pentobarbital-induced sleeping behaviors and non-rapid eye movement (NREM) sleep in rodents. *Nat. Prod. Sci.* **21**, 219-225.
- Choi, J. J., Oh, E.-H., Lee, M. K., Chung, Y. B., Hong, J. T. and Oh, K.-W. (2014) *Gastrodiae Rhizoma* ethanol extract enhances pentobarbital-induced sleeping behaviors and rapid eye movement sleep via the activation of GABA_A-ergic transmission in rodents. *Evid. Based Complement. Alternat. Med.* **2014**, 426843.
- Collinson, N., Kuenzi, F. M., Jarolimek, W., Maubach, K. A., Cothliff,

- R., Sur, C., Smith, A., Otu, F. M., Howell, O. and Atack, J. R. (2002) Enhanced learning and memory and altered GABAergic synaptic transmission in mice lacking the $\alpha 5$ subunit of the GABAA Receptor. *J. Neurosci.* **22**, 5572-5580.
- Crestani, F., Keist, R., Fritschy, J.-M., Benke, D., Vogt, K., Prut, L., Blüthmann, H., Möhler, H. and Rudolph, U. (2002) Trace fear conditioning involves hippocampal $\alpha 5$ GABAA receptors. *Proc. Natl. Acad. Sci. U.S.A.* **99**, 8980-8985.
- Crestani, F., Löw, K., Keist, R., Mandelli, M.-J., Möhler, H. and Rudolph, U. (2001) Molecular targets for the myorelaxant action of diazepam. *Mol. Pharmacol.* **59**, 442-445.
- Di Bella, G., Gualano, L. and Di Bella, L. (2017) Melatonin with adenosine solubilized in water and stabilized with glycine for oncological treatment—technical preparation, effectivity and clinical findings. *Neuro Endocrinol. Lett.* **38**, 465-474.
- Doghranj, K. (2006) The epidemiology and diagnosis of insomnia. *Am. J. Manag. Care* **12**, S214-S220.
- Dujardin, S., Pijpers, A. and Pevernagie, D. (2018) Prescription drugs used in insomnia. *Sleep Med. Clin.* **13**, 169-182.
- Grønli, J., Fiske, E., Murison, R., Bjorvatn, B., Sørensen, E., Ursin, R. and Portas, C. M. (2007) Extracellular levels of serotonin and GABA in the hippocampus after chronic mild stress in rats. A microdialysis study in an animal model of depression. *Behav. Brain Res.* **181**, 42-51.
- Han, H., Ma, Y., Eun, J.-S., Hong, J.-T. and Oh, K.-W. (2008) Anxiolytic-like effects of cyclopeptide fraction alkaloids of *Zizyphi Spinosi* semen: possible involvement of GABA_A receptors. *Biomol. Ther. (Seoul)* **16**, 261-269.
- Han, H., Ma, Y., Eun, J. S., Li, R., Hong, J.-T., Lee, M.-K. and Oh, K.-W. (2009) Anxiolytic-like effects of sanjoinine A isolated from *Zizyphi Spinosi* Semen: possible involvement of GABAergic transmission. *Pharmacol. Biochem. Behav.* **92**, 206-213.
- Han, H. J., Kim, H. Y., Choi, J. J., Ahn, S.-Y., Lee, S.-H., Oh, K.-W. and Kim, S.-Y. (2013) Effects of red ginseng extract on sleeping behaviors in human volunteers. *J. Ethnopharmacol.* **149**, 597-599.
- Han, T. H., Lee, K., Park, J. B., Ahn, D., Park, J.-H., Kim, D.-Y., Stern, J. E., Lee, S. Y. and Ryu, P. D. (2010) Reduction in synaptic GABA release contributes to target-selective elevation of PVN neuronal activity in rats with myocardial infarction. *Am. J. Physiol. Regul. Integr. Comp. Physiol.* **299**, R129-R139.
- Haque, A. M., Hashimoto, M., Katakura, M., Hara, Y. and Shido, O. (2008) Green tea catechins prevent cognitive deficits caused by A β 1-40 in rats. *J. Nutr. Biochem.* **19**, 619-626.
- Hirano, T. (1991) Differential pre- and postsynaptic mechanisms for synaptic potentiation and depression between a granule cell and a purkinje cell in rat cerebellar culture. *Synapse* **7**, 321-323.
- Hu, Z., Lee, C.-I., Shah, V. K., Oh, E.-H., Han, J.-Y., Bae, J.-R., Lee, K., Chong, M.-S., Hong, J. T. and Oh, K.-W. (2013) Cordycepin increases nonrapid eye movement sleep via adenosine receptors in rats. *Evid. Based Complement. Alternat. Med.* **2013**, 840134.
- Igarashi, M. and Miyazaki, Y. (2013) A review on bioactivities of perilla: progress in research on the functions of perilla as medicine and food. *Evid. Based Complement. Alternat. Med.* **2013**, 925342.
- Jacobson, L. H., Hoyer, D., Fehlmann, D., Bettler, B., Kaupmann, K. and Cryan, J. F. (2017) Blunted 5-HT 1A receptor-mediated responses and antidepressant-like behavior in mice lacking the GABA B1a but not GABA B1b subunit isoforms. *Psychopharmacology* **234**, 1511-1523.
- Jafari, B. and Mohsenin, V. (2010) Polysomnography. *Clin Chest Med.* **31**, 287-297.
- Johnston, G. A., Hanrahan, J. R., Chebib, M., Duke, R. K. and Mewett, K. N. (2006) Modulation of ionotropic GABA receptors by natural products of plant origin. *Adv. Pharmacol.* **54**, 285-316.
- Kim, C.-S., Jo, Y.-J., Park, S.-H., Kim, H.-J., Han, J.-Y., Hong, J.-T., Cheong, J.-H. and Oh, K.-W. (2010) Anti-stress effects of ginsenoside Rg 3-standardized ginseng extract in restraint stressed animals. *Biomol. Ther. (Seoul)* **18**, 219-225.
- Kim, J.-W., Han, J.-Y., Hong, J. T., Li, R., Eun, J. S. and Oh, K.-W. (2011) Ethanol extract of the flower *Chrysanthemum morifolium* augments pentobarbital-induced sleep behaviors: involvement of Cl⁻ channel activation. *Evid. Based Complement. Alternat. Med.* **2011**, 109164.
- Kim, J.-W., Kim, C.-S., Hu, Z., Han, J.-Y., Kim, S. K., Yoo, S.-K., Yeo, Y. M., Chong, M. S., Lee, K. and Hong, J. T. (2012) Enhancement of pentobarbital-induced sleep by apigenin through chloride ion channel activation. *Arch. Pharm. Res.* **35**, 367-373.
- Kimura, T., Saunders, P., Kim, H., Rheu, H., Oh, K. and Ho, I. (1994) Interactions of ginsenosides with ligand-bindings of GABA(A) and GABA(B) receptors. *Gen. Pharmacol.* **25**, 193-199.
- Kwon, Y. O., Hong, J. T. and Oh, K.-W. (2017) Rosmarinic acid potentiates pentobarbital-induced sleep behaviors and non-rapid eye movement (NREM) sleep through the activation of GABAergic systems. *Biomol. Ther. (Seoul)* **25**, 105-111.
- Löw, K., Crestani, F., Keist, R., Benke, D., Brünig, I., Benson, J. A., Fritschy, J.-M., Rülcke, T., Blüthmann, H. and Möhler, H. (2000) Molecular and neuronal substrate for the selective attenuation of anxiety. *Science* **290**, 131-134.
- Lee, C.-I., Han, J.-Y., Hong, J. T. and Oh, K.-W. (2013) 3, 4, 5-Tri-methoxycinnamic acid (TMCA), one of the constituents of *Polygalae Radix* enhances pentobarbital-induced sleeping behaviors via GABA_A ergic systems in mice. *Arch. Pharm. Res.* **36**, 1244-1251.
- Lee, Y.-J., Choi, D.-Y., Lee, Y. K., Lee, Y. M., Han, S. B., Kim, Y. H., Kim, K. H., Nam, S.-Y., Lee, B. J. and Kang, J.-K. (2012) 4-O-methylhonokiol prevents memory impairment in the Tg2576 transgenic mice model of Alzheimer's disease via regulation of β -secretase activity. *J. Alzheimers Dis.* **29**, 677-690.
- Lee, Y. K., Song, J. K., Choi, I. S., Jeong, J. H., Moon, D. C., Yun, Y. P., Han, S. B., Oh, K.-W. and Hong, J. T. (2010) Neurotrophic activity of obovatol on the cultured embryonic rat neuronal cells by increase of neurotrophin release through activation of ERK pathway. *Eur. J. Pharmacol.* **649**, 168-176.
- Leiser, S. C., Li, Y., Pehrson, A. L., Dale, E., Smagin, G. and Sanchez, C. (2015) Serotonergic regulation of prefrontal cortical circuitries involved in cognitive processing: a review of individual 5-HT receptor mechanisms and concerted effects of 5-HT receptors exemplified by the multimodal antidepressant vortioxetine. *ACS Chem. Neurosci.* **6**, 970-986.
- Lo, H. H., Valentovic, M. A., Rankin, G. O. and Brown, P. I. (1994) Effect of chemical form, route of administration and vehicle on 3, 5-dichloroaniline-induced nephrotoxicity in the fischer 344 rat. *J. Appl. Toxicol.* **14**, 417-422.
- Ma, Y., Han, H., Eun, J. S., Kim, H.-C., Hong, J.-T. and Oh, K.-W. (2007) Sanjoinine A isolated from *Zizyphi Spinosi* Semen augments pentobarbital-induced sleeping behaviors through the modification of GABA-ergic systems. *Biol. Pharm. Bull.* **30**, 1748-1753.
- Ma, Y., Kim, Y. B., Nam, S. Y., CHEONG, J. H., Park, S. H., Kim, H. J., Hong, J. T. and OH, K. W. (2009a) Effects of red ginseng extract on sleep architecture and electroencephalogram power spectra in rats. *Sleep Biol. Rhythms* **7**, 78-83.
- Ma, Y., Ma, H., Eun, J. S., Nam, S.-Y., Kim, Y.-B., Hong, J.-T., Lee, M.-K. and Oh, K.-W. (2009b) Methanol extract of *Longanae Arillus* augments pentobarbital-induced sleep behaviors through the modification of GABAergic systems. *J. Ethnopharmacol.* **122**, 245-250.
- Ma, Y., Yun, S.-R., Nam, S.-Y., Kim, Y.-B., Hong, J.-T., Kim, Y., Choi, H., Lee, K. and Oh, K.-W. (2008) Protective effects of sanjoinine A against N-methyl-D-aspartate-induced seizure. *Biol. Pharm. Bull.* **31**, 1749-1754.
- Maruyama, K., Nakamura, T., Yoshihara, T., Fukutomi, J., Sugiyama, K., Hattorim, K., Ohnuki, T., Watanabe, K. and Nagatomo, T. (1998) Tamsulosin: assessment of affinity of 3H-prazosin bindings to two $\alpha 1$ -adrenoceptor subtypes ($\alpha 1H$ and $\alpha 1L$) in bovine prostate and rat heart and brain. *Gen. Pharmacol.* **31**, 597-600.
- Matsumoto, K., Kohno, S.-I., Qjima, K., Tezuka, Y., Kadota, S. and Watanabe, H. (1998) Effects of methylenechloride-soluble fraction of Japanese angelica root extract, ligustilide and butylidenephthalide, on pentobarbital sleep in group-housed and socially isolated mice. *Life Sci.* **62**, 2073-2082.
- McKernan, R., Rosahl, T., Reynolds, D., Sur, C., Wafford, K., Atack, J., Farrar, S., Myers, J., Cook, G. and Ferris, P. (2000) Sedative but not anxiolytic properties of benzodiazepines are mediated by the GABA_A receptor $\alpha 1$ subtype. *Nat. Neurosci.* **3**, 587-592.
- Mieda, M. (2017) The roles of orexins in sleep/wake regulation. *Neurosci. Res.* **118**, 56-65.
- Nguyen, M., Nguyen, T., Kasai, R., Ito, A., Yamasaki, K. and Tanaka,

- O. (1993) Saponins from Vietnamese ginseng, *Panax vietnamensis* Ha et Grushv. Collected in central Vietnam. I. *Chem. Pharm. Bull.* **41**, 2010-2014.
- Okuyama, E., Ebihara, H., Takeuchi, H. and Yamazaki, M. (1999) Adenosine, the anxiolytic-like principle of the *Arillus* of *Euphoria longana*. *Planta Med.* **65**, 115-119.
- Olsen, R. W. (1981) GABA-benzodiazepine-barbiturate receptor interactions. *J. Neurochem.* **37**, 1-13.
- Park, J., Kim, S. Y., Cha, G.-H., Lee, S. B., Kim, S. and Chung, J. (2005) *Drosophila* DJ-1 mutants show oxidative stress-sensitive locomotive dysfunction. *Gene* **361**, 133-139.
- Park, K.-S., Han, J.-Y., Moon, D.-C., Hong, J. T. and Oh, K.-W. (2011) (-)-Epigallocatechin-3-O-gallate augments pentobarbital-induced sleeping behaviors through Cl⁻ channel activation. *J. Med. Food* **14**, 1456-1462.
- Park, K.-S., Oh, J. H., Yoo, H.-S., Lee, Y.-M., Lee, M.-K., Hong, J. T. and Oh, K.-W. (2010) (-)-Epigallocatechin-3-O-gallate (EGCG) reverses caffeine-induced anxiogenic-like effects. *Neurosci. Lett.* **481**, 131-134.
- Park, K. S., Da Lee, R., Kang, S.-K., Han, S. Y., Park, K. L., Yang, K. H., Song, Y. S., Park, H. J., Lee, Y. M. and Yun, Y. P. (2004) Neuronal differentiation of embryonic midbrain cells by upregulation of peroxisome proliferator-activated receptor-gamma via the JNK-dependent pathway. *Exp. Cell Res.* **297**, 424-433.
- Perentos, N., Nicol, A., Martins, A., Stewart, J., Taylor, P. and Morton, A. J. (2017) Techniques for chronic monitoring of brain activity in freely moving sheep using wireless EEG recording. *J. Neurosci. Methods* **279**, 87-100.
- Rao, S., Liu, S., Zou, L., Jia, T., Zhao, S., Wu, B., Yi, Z., Wang, S., Xue, Y. and Gao, Y. (2017) The effect of sinomenine in diabetic neuropathic pain mediated by the P2X₃ receptor in dorsal root ganglia. *Purinergic Signal.* **13**, 227-235.
- Rašković, A., Milanović, I., Pavlović, N., Čebović, T., Vukmirović, S. and Mikov, M. (2014) Antioxidant activity of rosemary (*Rosmarinus officinalis* L.) essential oil and its hepatoprotective potential. *BMC Complement. Altern. Med.* **14**, 225.
- Rosi, S., Ramirez-Amaya, V., Hauss-Wegrzyniak, B. and Wenk, G. L. (2004) Chronic brain inflammation leads to a decline in hippocampal NMDA-R1 receptors. *J. Neuroinflammation* **1**, 12.
- Rudolph, R. L. and Feiger, A. D. (1999) A double-blind, randomized, placebo-controlled trial of once-daily venlafaxine extended release (XR) and fluoxetine for the treatment of depression. *J. Affect. Disord.* **56**, 171-181.
- Rudolph, U. and Möhler, H. (2006) GABA-based therapeutic approaches: GABA_A receptor subtype functions. *Curr. Opin. Pharmacol.* **6**, 18-23.
- Rundell, O. and Jones, R. (1990) Polysomnography methods and interpretations. *Otolaryngol. Clin. North Am.* **23**, 583-592.
- Sanford, L. D., Yang, L., Liu, X. and Tang, X. (2006) Effects of tetrodotoxin (TTX) inactivation of the central nucleus of the amygdala (CNA) on dark period sleep and activity. *Brain Res.* **1084**, 80-88.
- Schwartz, J., Neukirchen, M., De Vilder, M.-C., Hornemann, B., Wolf, C., Gärtner, J. and Thomas, M. (2017) SOP-Depression und Angst in der Palliativmedizin. *Der Onkologe* **23**, 756-763.
- Seo, J.-J., Lee, S.-H., Lee, Y.-S., Kwon, B.-M., Ma, Y., Hwang, B.-Y., Hong, J.-T. and Oh, K.-W. (2007) Anxiolytic-like effects of obovatol isolated from *Magnolia obovata*: involvement of GABA/benzodiazepine receptors complex. *Prog. Neuropsychopharmacol. Biol. Psychiatry* **31**, 1363-1369.
- Shah, P., Singh, S. and Kumar, A. (2015) Combined effect of hydroethanolic extracts of *Murraya koenigii* and *Phyllanthus niruri* leaves on paracetamol and ethanol-induced toxicity in HepG2 cell line. *Current Science (00113891)* **109**, 1320-1326.
- Shah, V. K., Choi, J. J., Han, J.-Y., Lee, M. K., Hong, J. T. and Oh, K.-W. (2014) Pachymic acid enhances pentobarbital-induced sleeping behaviors via GABA_A-ergic systems in mice. *Biomol. Ther. (Seoul)* **22**, 314-320.
- Starks, S. A., Outlaw, F., Graff, J. C., Likes, W., White-Means, S., Melaro, L. and Wicks, M. N. (2018) Quality of life and african american women who are family caregivers: a literature review with implications for psychiatric mental health advanced practice registered nurses. *Issues Ment. Health Nurs.* **39**, 467-481.
- Takagi, K., Saito, H. and Tsuchiya, M. (1972) Pharmacological studies of *Panax ginseng* root: pharmacological properties of a crude saponin fraction. *Jpn. J. Pharmacol.* **22**, 339-346.
- Takeda, H., Tsuji, M., Inazu, M., Egashira, T. and Matsumiya, T. (2002) Rosmarinic acid and caffeic acid produce antidepressive-like effect in the forced swimming test in mice. *Eur. J. Pharmacol.* **449**, 261-267.
- Tatarczynska, E., Klodzinska, A., Stachowicz, K. and Chojnacka-Wojcik, E. (2004) Effects of a selective 5-HT_{1B} receptor agonist and antagonists in animal models of anxiety and depression. *Behav. Pharmacol.* **15**, 523-534.
- Ticku, M. K. and Maksay, G. (1983) Convulsant/depressant site of action at the allosteric benzodiazepine-GABA receptor-ionophore complex. *Life Sci.* **33**, 2363-2375.
- Ursin, R. (2002) Serotonin and sleep. *Sleep Med. Rev.* **6**, 55-67.
- Vallverdú-Queralt, A., Regueiro, J., Martínez-Huélamo, M., Alvarenga, J. F. R., Leal, L. N. and Lamuela-Raventos, R. M. (2014) A comprehensive study on the phenolic profile of widely used culinary herbs and spices: rosemary, thyme, oregano, cinnamon, cumin and bay. *Food Chem.* **154**, 299-307.
- Vignes, M., Maurice, T., Lanté, F., Nedjar, M., Thethi, K., Guiramand, J. and Récasens, M. (2006) Anxiolytic properties of green tea polyphenol (-)-epigallocatechin gallate (EGCG). *Brain Res.* **1110**, 102-115.
- Viola, H., Wasowski, C., De Stein, M. L., Wolfman, C., Silveira, R., Dajas, F., Medina, J. and Paladini, A. (1995) Apigenin, a component of *Matricaria recutita* flowers, is a central benzodiazepine receptors-ligand with anxiolytic effects. *Planta Med.* **61**, 213-216.
- Wang, Z. J. and Liu, J. F. (2016) The molecular basis of insomnia: implication for therapeutic approaches. *Drug Dev. Res.* **77**, 427-436.
- Watanabe, K., Watanabe, H., Goto, Y., Shimizu, M. and Maeda-Hagiwara, M. (1983) γ -Butyrolactone enhances the activity of GABA in the gastric acid secretion of anesthetized rats. *Jpn. J. Pharmacol.* **33**, 1163-1169.
- Woo, J. H., Ha, T.-W., Kang, J.-S., Hong, J. T. and Oh, K.-W. (2017) Potentiation of decursinol angelate on pentobarbital-induced sleeping behaviors via the activation of GABA_A-ergic systems in rodents. *Korean J. Physiol. Pharmacol.* **21**, 27-36.
- Yang, J.-E., Kim, S.-Y., Im, W.-T. and Yi, T.-H. (2011a) *Flavobacterium ginsenosidimutans* sp. nov., a bacterium with ginsenoside converting activity isolated from soil of a ginseng field. *Int. J. Syst. Evol. Microbiol.* **61**, 1408-1412.
- Yang, S.-L., Han, J.-Y., Kim, Y.-B., Nam, S.-Y., Song, S., Hong, J. T. and Oh, K.-W. (2011b) Increased non-rapid eye movement sleep by cocaine withdrawal: possible involvement of A_{2A} receptors. *Arch. Pharm. Res.* **34**, 281-287.
- Yi, P.-L., Lin, C.-P., Tsai, C.-H., Lin, J.-G. and Cang, F.-C. (2007) The involvement of serotonin receptors in suanzaorentang-induced sleep alteration. *J. Biomed. Sci.* **14**, 829-840.